XELJANZ®

XELJANZ® empowers you in your struggle with joint pain caused by autoimmunity by providing you with rapid and efficient relief. It is convenient and equipped with a good safety profile.

What is XELJANZ®?

What is XELJANZ®?1

  • XELJANZ® contains the active ingredient tofacitinib1
  • XELJANZ® is the first-in-class of a new oral treatment that targets the Janus kinase (JAK) pathways2
  • Excessive production of cytokines causes joint pain and symptoms through activation of the JAK pathways2
How to take XELJANZ®?

How to take XELJANZ®?1

如何服用捷抑炎®？
  • 捷抑炎®可單獨使用或與甲氨蝶呤或其他非生物製劑類藥物合併使用XELJANZ® may be used alone or in combination with methotrexate or other non-biological therapies
  • 捷抑炎®的建議劑量為每日兩次，每次5毫克The recommended dose of XELJANZ® is 5mg twice daily
  • 捷抑炎®為口服藥物，可於飯前或飯後服用XELJANZ® should be taken orally, with or without food
  • 捷抑炎®存放於攝氏30度或以下Store at 30oC or below
Efficacy of XELJANZ®

Efficacy of XELJANZ®

An oral JAK inhibitor proven to deliver a powerful, rapid relief of joint pain caused by autoimmunity3

START FIRST WITH XELJANZ®Start with XELJANZ
STAY WITH XELJANZ®Stay with XELJANZ

 

Safety of XELJANZ®

XELJANZ® offers a consistent safety profile

Consistent safety data with

XELJANZ® offers a consistent safety profile

Consistent safety profile
The safety profile of XELJANZ® is consistent either as monotherapy or combination therapy8
No increase in selected adverse events
No significant increases in incidence rates (IR) of selected adverse events over 78 months*8
* Please consult your doctor or your pharmacist for more information.
Shut down